Xarelto Lawsuit Update: New Allegations Made in Internal Bleeding Lawsuits

October 13, 2015 – – BloodThinnerHelp.com reports today on the new allegations that are being made in the lawsuits filed against the manufacturers of Xarelto. All of the federally filed lawsuits have been consolidated into a federal multidistrict litigation because they made similar allegations against the same defendants, the defendants being Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. For more detailed information about the lawsuits, click here.

To this date, a majority of the lawsuit filed, not just in the federal MDL but also in the mass tort group based out of Philadelphia, make similar allegations, mainly that Xarelto was prescribed to prevent blood clots but due to the nature in which Xarelto operates, the drug can cause uncontrollable internal bleeding which can lead to serious injury and/or death.

Xarelto’s Dangerous Difference:

Xarelto is different from blood thinners because it is a part of a new class of anticoagulants known as Xa inhibitors. Xa inhibitors work by blocking the chemical in the blood that is responsible for making blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood’s ability to clot. This is problematic because there is no antidote to reverse the effects of Xarelto, meaning that if a patient is taking Xarelto and suffers an internal bleeding injury, there is no way to stop the bleeding.

Xarelto Lawsuit Allegations:

The following allegations are the basis for the Xarelto lawsuits:

– Xarelto’s manufactures failed to warn doctors and patients about the real risks of the drug, specifically the irreversible uncontrollable internal bleeding that may occur.

– Xarelto has a dangerous defect in its design because there is no safe anticoagulant solution. This poses greater risks of internal bleeding to patients because there is no reversal agent.

– Xarelto’s manufacturers fraudulently concealed knowledge of irreversible life threatening events and how doctors should intervene and stabilize patients.

– Xarelto’s manufacturers were negligent in placing the drug onto the market with the knowledge that there was no antidote.

-Xarelto’s manufacturers were negligent in the marketing of Xarelto with their misrepresentation of Xarelto as a safe blood thinner.

– Xarelto does not provide greater benefits than other products already on the market in a safer manner such as Warfarin.

Currently, the lawsuits filed in the Xarelto are still in the pretrial stages of litigation, but the dates for the initial trials have been set. The first trial will take place in the United States District Court for the Eastern District of Louisiana in early 2017 with three more trials throughout the first half of 2017 following it.

“We strongly encourage anyone who feels that they have been harmed by Xarelto to contact us immediately.” Xarelto attorney Marc Goldich said, “If the manufacturers of Xarelto were aware of the dangers of the drug yet put it to market anyway, they deserve to be held responsible.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60004691